

Tumor (cases)	Dataset (# genes)	Outcome Variable	Binary Marker	HR	95% CI	P-value	Continuous Marker	HR	95% CI	P-value
Breast (295)	van de Vijver (173)	OS	Sig. P vs A	3.69	2.25 to 6.06	2.21E-07	Signature Score	2.33	1.74 to 3.14	1.98E-08
		DDFS	Sig. P vs A	2.48	1.65 to 3.73	1.15E-05	Signature Score	1.80	1.40 to 2.32	4.10E-06
		OS (5-year)	Sig. P vs A	4.13	2.11 to 8.10	3.63E-05				
		DDFS (5-year)	Sig. P vs A	3.06	1.89 to 4.95	5.19E-06				
Breast (99)	Sotiriou (92)	BCS	Sig. P vs A	1.87	0.95 to 3.68	0.069	Signature Score	2.33	1.14 to 4.74	0.020
		RFS	Sig. P vs A	1.89	1.02 to 3.48	0.042	Signature Score	2.13	1.14 to 3.99	0.018
		BCS (5-year)	Sig. P vs A	2.70	1.13 to 6.42	0.025				
		RFS (5-year)	Sig. P vs A	1.95	0.99 to 3.83	0.053				
Prostate (79)	Glinsky (152)	DDFS	Sig. P vs A	2.27	1.17 to 4.39	0.015	Signature Score	2.87	1.13 to 7.32	0.027
		DDFS (5-year)	Sig. P vs A	2.01	1.00 to 4.04	0.051				
Bladder (80) (32)	Blaveri (115)	OS	Sig. P vs A	1.38	0.76 to 2.49	0.292	Signature Score	1.87	1.01 to 3.48	0.047
		OS	Sig. P vs A "robust"	3.89	1.29 to 11.7	0.016				
		OS (5-year*)	Sig. P vs A "robust"	3.89	1.29 to 11.7	0.016				
Lung (86)	Beer (79)	OS	Sig. P vs A	2.00	0.85 to 4.7	0.112	Signature Score	1.56	0.82 to 2.95	0.176
		OS (5-year)	Sig. P vs A	2.31	0.94 to 5.66	0.068				
Breast (191)	this study (1)	DDFS	Stathmin IHC + vs -	1.85	0.93 to 3.68	0.081	Stathmin Continuous	1.05	0.98 to 1.12	0.183
		DDFS (5-year)	Stathmin IHC + vs -	2.38	1.17 to 4.84	0.016	Stathmin Continuous	1.08	1.01 to 1.16	0.036
		DDFS (2-year)	Stathmin IHC + vs -	4.09	1.72 to 9.76	0.001	Stathmin Continuous	1.16	1.05 to 1.29	0.004

Markers are as follows: PTEN-loss signature Present vs. Absent (Sig. P vs A), PTEN-loss signature correlation as a continuous variable (Signature Score), stathmin immunohistochemistry dichotomized high vs. low (Stathmin IHC + vs -), stathmin IHC score as a continuous variable (Stathmin Score). Outcome variables (overall survival, OS; distant disease-free survival, DDFS; breast cancer-specific survival, BCS; recurrence-free survival, RFS) are analyzed over the complete follow-up period (see Fig. 2) unless otherwise noted in parentheses. The number of mapped signature genes to each platform are indicated in parenthesis after the Dataset. "Robust" classifications have correlations >0.2 to either Signature Present or Absent centroids and the number of cases above this threshold is indicated under the Tumor column. Computed hazard ratios (HR), 95% confidence intervals (95% CI), and P-values are shown. Note, the proportional hazards assumption was not met for the 5-year and complete follow-up analyses of DDFS for the analyses by high and low stathmin IHC. * "Robust" OS analysis over the complete and 5-year follow-up periods for the Blaveri bladder cancer dataset yielded the exact same result.